Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]        
Net loss attributable MAIA Biotechnology, Inc. shareholders $ (3,305,883) $ (3,430,714) $ (7,170,306) $ (4,414,708)
Foreign currency translation adjustment (5,866)   (4,145)  
Comprehensive loss to MAIA Biotechnology, Inc. shareholders $ (3,311,749) $ (3,430,714) $ (7,174,451) $ (4,414,708)